RxDoctor Payments Data

Deshay Scandrick

Family · Dayton, OHNPI 1851531628

Payments from drug & device makers

$525in general payments, 2019–2025

Across 13 payments — averaging $40.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$172
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$123
  • Novo Nordisk$77
  • AbbVie$71
  • Otsuka America Pharmaceutical, Inc.$23
  • Bayer$17
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525 in reported general payments places this provider in the 55th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$25,278
Medicare patients
175
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$103,234
TrulicityDulaglutide32$42,912
XareltoRivaroxaban22$23,467
JardianceEmpagliflozin22$15,925
JanuviaSitagliptin Phosphate21$15,179
LinzessLinaclotide27$13,991
RybelsusSemaglutide11$12,017
MounjaroTirzepatide11$11,499
EliquisApixaban14$10,311
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$9,545
Tresiba Flextouch U-100Insulin Degludec14$7,993
Emgality PenGalcanezumab-Gnlm11$7,878
FarxigaDapagliflozin Propanediol12$6,879
SymbicortBudesonide/Formoterol Fumarate20$4,459
Albuterol Sulfate HfaAlbuterol Sulfate226$4,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$77$115,251104 claims
AbbVieLinzess$71$13,99127 claims
AstraZenecaFarxiga, Symbicort$15$11,33832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →